Background: Central/abdominal obesity, systemic hypertension, insulin resistance (IR) or type 2 diabetes mellitus (T2DM), and atherogenic dyslipidemia are among the clinical disorders that make up metabolic syndrome (MetS). The present study was conducted to assess serum Apelin level in type II diabetic mellitus patients. Materials & Methods:70 type II diabetes mellitus patients of both genders were selected. Fasting blood glucose (FBG), triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) and Apelin (ng/mL) level was measured among subjects with metabolic and non- metabolic syndrome. Results: Out of 70 patients, 43 were males and 27 were females. The mean age (years) in age in patients with MetS and without MetS was 46.2 years and 45.4 years respectively. BMI (kg/m2) was 26.7 and 26.2, WC (cm) was 106.2 and 97.6, SBP (mm Hg) was 126.4 and 116.4, DBP (mm Hg) was 82.5 and 74.0, FBG (mg/dL) was 172.0 and 116.4, TG (mg/dL) was 196.4 and 130.6, HDL-C (mg/d L) was 41.5 and 46.2, Apelin level was 230.6 ng/mL and 428.4 ng/mL respectively. The difference was significant (P< 0.05). Conclusion: The determination of serum apelin may contribute to the evaluation of theMetS occurrence in T2DM patients.